Volver a Agenda
Session Chair(s)
Karen Lynn Price, PHD
Senior Research Fellow, Statistical Innovation Center/Design Hub
Eli Lilly and Company, United States
Learning Objective : Describe the efforts of the DIA Bayesian Scientific Working Group; Examine the value of the Bayesian approach across drug development, with a focus on comparative effectiveness research (CER); Discuss gaps in the use of Bayesian methods for CER including ways to meet gaps; Identify opportunities to collaborate in the future with the CER Scientific Working Group and Evidence-based Medicine Community, via open conversation across membership.
Speaker(s)
Bayesian Evidence Synthesis and Network Meta-Analysis in Context of CER
Bradley P. Carlin, PHD, MS
PharmaLex, United States
Senior Advisor, Data Science and Statistics
FDA Perspective
Ram Tiwari, PHD, MS
Bristol Myres Squibb , United States
Head of Statistical Methodology
Panelist
Matthew D. Rotelli, PHD, MS
Eli Lilly and Company, United States
Vice President, Bioethics
¿Tiene una cuenta?